Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 11/20 | 0.80 |
| ▸ | NR1H3 | Q13133 | 11/20 | 0.80 |
| ▸ | POLA1 | P09884 | 4/20 | 0.72 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.66 |
| ▸ | SOD1 | P00441 | 1/20 | 0.64 |
| ▸ | RXRA | P19793 | 1/20 | 0.64 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.64 |
| ▸ | CDK2 | P24941 | 1/20 | 0.64 |
| ▸ | RXRB | P28702 | 1/20 | 0.64 |
| ▸ | RXRG | P48443 | 1/20 | 0.64 |
| ▸ | KARS1 | Q15046 | 1/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.63 |
| ▸ | APEX1 | P27695 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Podocaric Acid SCHEMBL31181390 | 1.00 | NR1H2 (0.80) | NR1H2NR1H3POLA1PDE4DSOD1 | |
| Podocaric Acid SCHEMBL32474685 | 1.00 | NR1H2 (0.80) | NR1H2NR1H3POLA1PDE4DSOD1 | |
| Podocaric Acid SCHEMBL14389445 | 1.00 | NR1H2 (0.80) | NR1H2NR1H3POLA1PDE4DSOD1 | |
| Podocaric Acid SCHEMBL6311820 | 1.00 | NR1H2 (0.80) | NR1H2NR1H3POLA1PDE4DSOD1 | |
| Podocaric Acid SCHEMBL6312979 | 0.99 | NR1H2 (0.78) | NR1H2NR1H3POLA1PDE4DSOD1 | |
| SCHEMBL14696167 | 0.91 | SOD1 (0.77) | NR1H2NR1H3POLA1PDE4DSOD1 | |
| SCHEMBL15588775 | 0.91 | SOD1 (0.77) | NR1H2NR1H3POLA1PDE4DSOD1 | |
| SCHEMBL7024094 | 0.91 | SOD1 (0.77) | NR1H2NR1H3POLA1PDE4DSOD1 | |
| SCHEMBL2993726 | 0.89 | NR1H2 (0.76) | NR1H2NR1H3SOD1 | |
| SCHEMBL20561234 | 0.89 | NR1H2 (0.76) | NR1H2NR1H3SOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 968 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4661890-A1 | PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS | Purdue Research Foundation (US) | 2025-12-17 | — | — | EP | claimed |
| WO-2025083496-A1 | COMPOSITIONS FOR SEBUM CONTROL | Dyson Operations PTE. LTD. (SG) | 2025-04-24 | — | — | WO | claimed |
| WO-2025071908-A1 | MALEATED FATTY IMIDAZOLINE DERIVATIVES FOR CORROSION INHIBITORS | CHAMPIONX LLC (US) | 2025-04-03 | — | — | WO | claimed |
| US-20250109503-A1 | MALEATED FATTY IMIDAZOLINE DERIVATIVES FOR CORROSION INHIBITORS | CHAMPIONX LLC (US) | 2025-04-03 | — | — | US | claimed |
| US-20250099553-A1 | COMPOSITION AND METHODS FOR MODULATION OF ELOVL2 | YOUHEALTH BIOTECH, LIMITED (KY) | 2025-03-27 | — | — | US | claimed |
| WO-2024167565-A1 | PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS | PURDUE RESEARCH FOUNDATION (US) | 2024-08-15 | — | — | WO | claimed |
| US-20220409551-A1 | COMPOSITION COMPRISING POLAR LIPIDS AND METHOD OF MAKING SAME | Vaxa Technologies Ltd. (IL) | 2022-12-29 | — | — | US | claimed |
| EP-4101835-A1 | 18F-SUBSTITUTED ESTERS OF CYCLOPROPANATED UNSATURATED FATTY ACIDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | Blanchette Rockefeller Neurosciences Institute (US) | 2022-12-14 | — | — | EP | claimed |
| US-20220151973-A1 | HALOGENATED ESTERS OF CYCLOPROPANATED UNSATURATED FATTY ACIDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | Synaptogenix, Inc. (US) | 2022-05-19 | — | — | US | claimed |
| EP-3986387-A1 | COMPOSITION COMPRISING POLAR LIPIDS AND METHOD OF MAKING SAME | Vaxa Technologies Ltd. (IL) | 2022-04-27 | — | — | EP | claimed |
| WO-2014043625-A1 | THERAPEUTIC NANOPARTICLES COMPRISING A THERAPEUTIC AGENT AND METHODS OF MAKING AND USING SAME | BIND THERAPEUTICS, INC. (US) | 2014-03-20 | — | — | WO | claimed |
| US-20120088720-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATI (US) | 2012-04-12 | — | — | US | claimed |
| US-20110250183-A1 | Combination Therapy for Treatment of Patients with Neurological Disorders and Cerebral Infarction | MOLEAC PTE. LTD. (SG) | 2011-10-13 | — | — | US | claimed |
| WO-2010118241-A2 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (US) | 2010-10-14 | — | — | WO | claimed |
| CN-1989093-A | Process for preparing enantiomerically pure 1,1'-spirobiindane-6,6'-diol derivatives | EASTMAN KODAK CO (US) | 2007-06-27 | — | — | CN | claimed |
| US-7214834-B2 | Process for preparing enantiomerically pure 1,1′-spirobiindane-6,6′-diol derivatives | EASTMAN KODAK COMPANY (US) | 2007-05-08 | — | — | US | claimed |
| EP-1768943-A1 | PROCESS FOR PREPARING ENANTIOMERICALLY PURE 1,1'-SPIROBIINDANE-6,6'-DIOL DERIVATIVES | EASTMAN KODAK COMPANY (US) | 2007-04-04 | — | — | EP | claimed |
| WO-2006019663-A1 | PROCESS FOR PREPARING ENANTIOMERICALLY PURE 1,1'-SPIROBIINDANE-6,6'-DIOL DERIVATIVES | EASTMAN KODAK COMPANY (US) | 2006-02-23 | — | — | WO | claimed |
| US-20060020150-A1 | Process for preparing enantiomerically pure 1,1'-spirobiindane-6,6'-diol derivatives | EASTMAN KODAK COMPANY | 2006-01-26 | — | — | US | claimed |
| US-4039334-A | ORGANIC SILVER SALT AND HALIDE, REDUCING AGENT, ROSIN | FUJI PHOTO FILM CO., LTD. (JA) | 1977-08-02 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060020150-A1 | Process for preparing enantiomerically pure 1,1'-spirobiindane-6,6'-diol derivatives | HSD11B1, PKD1, REN | NR1H2 126/4885NR1H3 129/4885POLA1 952/4885 |
| US-20220409551-A1 | COMPOSITION COMPRISING POLAR LIPIDS AND METHOD OF MAKING SAME | PHOSPHO1, CNR2, ELOVL3 | NR1H2 69/4885NR1H3 39/4885POLA1 2826/4885 |
| US-20250109503-A1 | MALEATED FATTY IMIDAZOLINE DERIVATIVES FOR CORROSION INHIBITORS | FASN, FFAR1, IGF1R | NR1H2 1708/4885NR1H3 1384/4885POLA1 3139/4885 |
| US-20220151973-A1 | HALOGENATED ESTERS OF CYCLOPROPANATED UNSATURATED FATTY ACIDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | PRKCH, PRKCA, PRKCD | NR1H2 214/4885NR1H3 163/4885POLA1 2693/4885 |
| US-20120088720-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | PTPRCAP, PTPRF, PTPRS | NR1H2 4830/4885NR1H3 4854/4885POLA1 2848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.